Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

InMed taps ATERA for 3D skin models
September 2017
SHARING OPTIONS:

VANCOUVER—Biopharmaceutical company InMed Pharmaceuticals Inc. and ATERA SAS have struck up a research and development collaboration under which ATERA will produce 3D human skin models of epidermolysis bullosa (EB) for evaluating the in-vitro drug efficacy of INM-750. The compound is InMed’s lead candidate, a proprietary, topical cannabinoid product candidate being developed as a therapy for EB and potentially other dermatological and wound-healing indications. ATERA will also assess the effectiveness of INM-750 when applied topically, using in-vitro 3D reconstructed human full thickness skin models of normal and EB-derived cells to determine the effects at the ultra-structural cellular and molecular levels. Preclinical models have shown that INM-750 has significant potential for addressing symptomatic improvement of EB in terms of accelerated wound healing and reducing itch, pain and inflammation.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.